Skip to content
AdminOct 26, 2021< 1 min read

FDA, Aetion expand RWE work to focus on inpatient COVID-19 therapies

FDA and Aetion announced they will use the Aetion Evidence Platform® to gather real-world evidence on inpatient COVID-19 therapies, with the goal of demonstrating how a platform-based approach can help advance regulatory knowledge on the use of RWE and also to provide a scalable infrastructure through which therapies for coronavirus and other future infectious diseases and pandemics can be rapidly developed and evaluated.

Read More

Admin

RELATED ARTICLES

AdminOct 21, 20213 min read

Aetion FDA | FDA selects Aetion Evidence Platform® to advance regulatory science and innovation

NEW YORK, NY, October 21, 2021 — Today, Aetion announces that it is expanding its relationship with the U.S. Food and Drug ...
Start Reading
AdminMay 8, 20232 min read

Aetion® Launches New Application for Descriptive Analytics and Fast, Reliable Insights

NEW YORK, May 8, 2023 - Aetion®, the global leader in real-world evidence technology and analytics, today announced the launch ...
Start Reading
AetionMar 31, 20253 min read

Aetion Launches Aetion® Evidence Platform Availability in AWS Marketplace, Accelerating Real-World Evidence Benefits for its Customers

Aetion’s industry-leading platform integrates advanced analytics, scalable workflows and actionable insights empowering ...
Start Reading